T/myeloid mixed-phenotype acute leukemia treated with venetoclax and decitabine: A case report
Citations

WEB OF SCIENCE

2
Citations

SCOPUS

0

초록

BACKGROUNDMixed-phenotype acute leukemia (MPAL) is characterized by acute undifferentiated leukemia with blasts co-expressing myeloid and lymphoid antigens. However, consensus regarding the ideal management strategy for MPAL is yet to be established, owing to its rarity.CASE SUMMARYA 55-year-old male was diagnosed with T/myeloid MPAL. Vincristine, prednisolone, daunorubicin, and L-asparaginase were administered as induction chemotherapy. Septic shock occurred 10 days after induction, and bone marrow examination following recovery from sepsis revealed refractory disease. Venetoclax and decitabine were administered as chemotherapy-free induction therapy to reduce the infection risk. There were no serious infections, including febrile neutropenia, at the end of the treatment. After receiving two additional cycles of venetoclax/decitabine, the patient underwent haploidentical peripheral blood stem-cell transplantation and achieved complete response (CR) to treatment.CONCLUSIONCR was maintained in a patient with MPAL who underwent haploidentical peripheral blood stem-cell transplantation after additional venetoclax/decitabine cycles.

키워드

Mixed-phenotype acute leukemiaVenetoclaxDecitabineCase reportACUTE LYMPHOBLASTIC-LEUKEMIAACUTE MYELOID-LEUKEMIACELL TRANSPLANTATIONSAFETY
제목
T/myeloid mixed-phenotype acute leukemia treated with venetoclax and decitabine: A case report
저자
Park, SungwooJeong, Eun JeongKang, Jung HunLee, Gyeong-WonGo, Se-IlLee, Dong-HyunKoh, Eun-Ha
DOI
10.12998/wjcc.v11.i26.6200
발행일
2023-09
유형
Article
저널명
World Journal of Clinical Cases
11
26
페이지
6200 ~ 6205